L-Carnitine Protective Effect in Nephrotoxicity
Clinical Study to Evaluate the Possible Protective Effect of L-Carnitine Against Cisplatin-Induced Nephrotoxicity
Tanta University
46 participants
Aug 10, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is: Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?
Eligibility
Inclusion Criteria7
- Male or female patients.
- Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy.
- Age between 18 and 75 years.
- No serious cardiopulmonary comorbidity which could impair involvement in the study.
- Creatinine clearance value above 50 mL/min/1.73 m².
- Patients who will scheduled to receive at least 3 cycles of cisplatin.
- Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure).
Exclusion Criteria10
- Pregnancy or lactation.
- Metastasis to the central nervous system.
- Psychiatric disorders.
- Prior treatment with platinum derivatives.
- Hypersensitivity to cisplatin, carboplatin or other platinum derivatives.
- Patients with active infection or any symptoms of sepsis.
- Acute renal failure or renal surgery within the last 3 months.
- Patients unfit for cisplatin (patients with impaired renal function, sensorineural hearing loss and cardiomyopathy).
- Patients with known history or current treatment with nephrotoxic agents.
- Taking other antioxidant supplements such as Vitamins C and E.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
L-carnitine 350 mg three times daily by oral.
placebo tablet three times daily by oral.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07108777